scispace - formally typeset
K

Kristen I. Mcmartin

Researcher at University of Toronto

Publications -  8
Citations -  399

Kristen I. Mcmartin is an academic researcher from University of Toronto. The author has contributed to research in topics: Pregnancy & Cotinine. The author has an hindex of 6, co-authored 8 publications receiving 383 citations.

Papers
More filters
Journal ArticleDOI

Pregnancy outcome following gestational exposure to organic solvents: a prospective controlled study.

TL;DR: Occupational exposure to organic solvents during pregnancy is associated with an increased risk of major fetal malformations, and this risk appears to be increased among women who report symptoms associated with organic solvent exposure.
Journal ArticleDOI

Pregnancy outcome following maternal organic solvent exposure: A meta‐analysis of epidemiologic studies

TL;DR: Maternal occupational exposure to organic solvents is associated with a tendency toward an increased risk for spontaneous abortion and additional studies may affect the trend.
Journal ArticleDOI

Lung tissue concentrations of nicotine in sudden infant death syndrome (SIDS).

TL;DR: Children who died from SIDS tended to have higher concentrations of nicotine in their lungs than control children, regardless of whether smoking was reported, and this results further support the relationship between environmental tobacco smoke and the risk of SIDS.
Journal ArticleDOI

The effect of chronic cocaine exposure throughout pregnancy on maternal and infant outcomes in the rhesus monkey.

TL;DR: It was concluded that, in a rhesus monkey model, chronic cocaine exposure throughout pregnancy had no significant effect on maternal outcome, but did significantly affect infant outcome as assessed in this investigation.
Journal ArticleDOI

Diagnosing Intrauterine exposure to cocaine by hair testing : Six years of clinical use

TL;DR: Because neonatal hair grows only during the last 4 months of pregnancy, positive Neonatal hair test results reflect maternal addiction, and this warrants close follow-up of the baby after release because of the high rate of postnatal risks secondary to suboptimal parental care andBecause of the proven perinatal risks inflicted by the drug itself.